Catalyst Pharmaceuticals to Present at JPMorgan’s Prestigious Healthcare Conference 2025

Catalyst Pharmaceuticals to Present at Prestigious J.P. Morgan Healthcare Conference

San Francisco, CA ⁤- Catalyst Pharmaceuticals ⁣(NASDAQ: CPRX), a leading biopharmaceutical company focused on developing innovative treatments for rare and debilitating diseases,⁣ announced today its participation in the highly ‍anticipated 43rd Annual J.P.Morgan Healthcare Conference.Richard J. Daly, President and CEO ⁤of Catalyst Pharmaceuticals, will deliver ⁣a presentation highlighting the ⁢company’s recent advancements and ‍future prospects‍ on Thursday, January 16, 2025, ⁤at 10:30 am PST.

The ⁣presentation will be‍ accessible to the public via live webcast through the Investors section of the Catalyst Pharmaceuticals ⁤website. A replay will be available for‍ a minimum of 30 days following the event, ⁤providing investors and interested parties with ample opportunity to ⁤access⁤ the information.

“We are excited to participate in this prestigious conference and share our progress with‍ the investment community,” said Daly. “The ⁣J.P. Morgan Healthcare Conference provides an⁣ invaluable platform to showcase our commitment to developing life-changing therapies for patients with unmet medical needs.”

Catalyst Pharmaceuticals has a ⁤strong ‍track record⁢ of success in bringing novel treatments to market,and the company’s presentation ‍at the J.P. Morgan Healthcare Conference is expected to generate meaningful interest among investors‍ and industry stakeholders.

Catalyst pharmaceuticals to Present ⁤at prestigious⁤ J.P. Morgan Healthcare Conference

Miami,FL ⁣ – Catalyst Pharmaceuticals,Inc.(NASDAQ: CPRX),‍ a biopharmaceutical company ⁣focused on⁣ developing and commercializing therapies for⁢ rare and debilitating diseases, announced today its ⁤participation in the highly anticipated 43rd Annual J.P. Morgan Healthcare Conference.

Richard J. Daly,President and CEO of Catalyst‍ Pharmaceuticals,will deliver a presentation on Thursday,January 16,2025,at 10:30 AM PST in ⁢San ⁢Francisco.

“We are excited to share our progress ⁤and vision for⁢ the future with the investment community at this premier⁣ healthcare event,” said Daly. “The J.P. Morgan‍ Healthcare Conference provides an invaluable platform to ⁤showcase our commitment to developing innovative treatments for patients in need.”

The presentation will be accessible via webcast‍ on the⁢ Investor relations⁤ section of the catalyst Pharmaceuticals website. A‍ replay will be available for at least 30 days following the event.

The J.P.Morgan Healthcare Conference is a leading industry event that brings⁤ together⁣ global leaders in the healthcare sector, including investors, pharmaceutical executives, and⁢ researchers. Catalyst’s⁤ participation underscores the company’s dedication to advancing its ‍pipeline of promising therapies‍ and its‍ commitment to openness with⁤ investors.

Catalyst Pharmaceuticals to present at Prestigious J.P. Morgan Healthcare Conference

CORAL ⁣GABLES, Fla., Dec. 16, 2024 – Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX),a biopharmaceutical company dedicated to ⁤developing treatments for rare and⁤ challenging diseases,announced today ⁢that President and CEO Richard J. daly will present at the 43rd Annual ⁤J.P. Morgan Healthcare Conference. The conference, a major event in the ⁤biotech and⁤ pharmaceutical industry, ‍will take place January 13-16, 2025, in San Francisco, CA.

This prominent platform offers Catalyst a valuable opportunity to showcase ⁤its latest⁤ advancements in novel medications and therapies.

Presentation Details:

Date: Thursday,January 16,2025
Time: 10:30 am PST
* Webcast: Link to Webcast

The webcast ⁣will also be accessible on the Investors section of the Catalyst Pharmaceuticals website.

This presentation⁢ marks a significant moment for Catalyst as⁤ it continues to make strides in its⁤ mission ⁢to ⁢improve the lives of patients with rare diseases.

Catalyst Pharmaceuticals to Present at‍ Prestigious J.P. Morgan Healthcare Conference

Coral Gables,⁣ FL ⁣–⁣ December 18, 2024 – Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a leading biopharmaceutical⁤ company⁢ dedicated to developing treatments for rare diseases, announced today that it will present at the renowned J.P. Morgan Healthcare Conference in San Francisco.

The presentation, scheduled for Thursday, January ⁣16, 2025, at 10:30 am PST, will provide an update on Catalyst’s progress and future plans. investors and other interested parties can access a live webcast of the presentation through the “Investors” section of the Catalyst ⁣Pharmaceuticals website at www.catalystpharma.com. A replay will be available for at least 30 days following the event.

“We are excited to⁣ share our latest advancements and vision for the⁤ future with the investment community at this prominent healthcare conference,” said [Insert Name and Title of Catalyst Pharmaceuticals Executive]. “Catalyst remains committed⁤ to delivering innovative therapies that improve the lives of patients with rare⁣ diseases, and we look forward to discussing our ongoing efforts in this importent area.”

About ⁣Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is ⁢a ⁤biopharmaceutical company focused on⁢ developing and commercializing therapies for rare diseases. With a proven track record of bringing life-changing treatments to market, Catalyst prioritizes patient access through comprehensive ⁢support services. Headquartered in Coral Gables, Florida, Catalyst⁢ was recently recognized as one of North America’s Fastest-Growing Companies on the ⁣2024 Deloitte Technology Fast 500™ List.

For more information,⁣ please visit www.catalystpharma.com.

Forward-Looking Statements

This press ‍release⁤ contains forward-looking statements within the meaning of the Private Securities Litigation Reform‍ Act of‍ 1995. These statements involve known and unknown risks and uncertainties that ⁢may cause Catalyst’s actual results to differ materially from those expressed or implied ⁢in such statements. Factors that could cause or contribute to such differences include, but ‍are not‍ limited to, ⁤those discussed in⁣ Catalyst’s Annual report on Form 10-K for ⁢the fiscal year 2023 and its other filings with the U.S.Securities and Exchange Commission. Catalyst does not undertake any obligation to ⁣update or revise any forward-looking statements, whether as a‍ result⁣ of new information, future events or otherwise.

Catalyst Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Coral Gables, FL ‍ – catalyst pharmaceuticals, Inc. (CPRX), ‍a biopharmaceutical company focused⁢ on developing treatments for rare ⁢diseases,⁣ announced today⁤ that it will present at⁢ the 41st Annual⁢ J.P. Morgan Healthcare Conference.

The presentation will take place ⁣on [Insert Date] at [Insert Time] ⁣ PST. Investors ⁣interested⁤ in learning more about Catalyst’s pipeline and progress ⁣can⁣ access the live webcast through the⁤ Investors section of the company’s website, www.catalystpharma.com.‍ A replay of the presentation will be‍ available on the website for at least 30 days following the event.Catalyst Pharmaceuticals is dedicated to improving the lives of patients with⁤ rare and ⁣debilitating diseases. The company’s focus on⁤ in-licensing, ⁣developing, and commercializing novel⁤ medicines makes it a key⁤ player in the field of rare disease therapeutics.

Catalyst Pharmaceuticals⁢ to⁣ Shine Spotlight ⁣on Rare Disease Treatments at J.P. Morgan healthcare Conference

San Francisco, CA, December 16, 2024 – Excitement is building for Catalyst Pharmaceuticals (NASDAQ: ⁤CPRX), a⁢ leading biopharmaceutical company specializing in innovative treatments for rare ⁢and debilitating diseases, as they prepare to take center stage at⁤ the prestigious 43rd Annual J.P. Morgan Healthcare Conference.

We spoke with Dr. [Expert name], a respected industry analyst with [Expert Credentials] about Catalyst’s participation and⁢ the potential impact of this high-profile event.

NewsDirect: Catalyst Pharma has positioned itself⁣ as a key player in the field of ‍rare diseases. What makes their participation in the⁤ J.P. Morgan Healthcare Conference so significant?

Dr. [Expert Name]: This conference is a gold‍ standard‍ in the healthcare industry. It attracts a who’s who‍ of ‍investors, researchers,⁤ and industry leaders. For ⁣Catalyst, this is a prime prospect to not only showcase their exciting pipeline‍ of treatments but also build relationships and garner crucial attention from the investment community.

NewsDirect: What specific advancements⁢ might Catalyst highlight during their presentation⁣ on January 16th?

Dr.[Expert Name]: We can expect Catalyst to focus on their recent progress in developing novel therapies for [Mention specific disease areas Catalyst focuses on]. Their presentation will likely delve into ⁣clinical trial results, new research findings, and their strategic plans for bringing these⁤ groundbreaking treatments to market.

NewsDirect: What message do you⁤ anticipate Catalyst ⁣will convey to investors and industry ⁣stakeholders?

Dr. [Expert Name]: I anticipate a strong emphasis on⁤ Catalyst’s ⁣commitment to improving the lives⁣ of patients with rare diseases. They will likely highlight their⁤ dedication to⁣ rigorous scientific research,their compassionate approach to patient care,and ⁤their vision for becoming a ⁣global leader in this vital therapeutic area.

NewsDirect: How might Catalyst’s presentation at the J.P. Morgan Healthcare Conference impact their future?

Dr. [Expert Name]: A compelling presentation can considerably boost ⁣investor confidence and generate⁣ excitement around Catalyst’s‍ future prospects. This, in turn, could lead to increased funding opportunities, stronger partnerships, and ultimately, a faster path⁣ to bringing life-changing treatments to patients⁣ who desperately need them.

The Takeaway:

Catalyst Pharmaceuticals’ participation in the J.P. Morgan Healthcare Conference is a testament to their leading role in the rare disease space. Their ⁣presentation promises to shed light on important advancements and reinforce their dedication to developing innovative therapies. the ⁣entire healthcare community will be watching closely as Catalyst ‍takes this crucial step toward achieving their ambitious goals.